Patents Assigned to Genmab A/S
  • Bispecific antibodies and methods for production thereof
    Patent number: 9212230
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 15, 2015
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren
  • Antibodies against CD38 for treatment of multiple myeloma
    Patent number: 9187565
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: November 17, 2015
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Use of effector-function-deficient antibodies for treatment of auto-immune diseases
    Patent number: 9181344
    Abstract: The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: November 10, 2015
    Assignee: GENMAB A/S
    Inventors: Mario Losen, Pilar Martinez-Martinez, Marc H. De Baets, Yvo Graus, Janine Schuurman, Paul Parren
  • Human antibody drug conjugates against tissue factor
    Patent number: 9168314
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 27, 2015
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 9150663
    Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Human antibodies against tissue factor and methods of use thereof
    Patent number: 9150658
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, David P. E. Satijn, Rene Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Antibody variants having modifications in the constant region
    Patent number: 9085625
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: July 21, 2015
    Assignee: Genmab A/S
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jau Van De Winkel, Janine Schuurman, Lgnace Laster
  • Monoclonal antibodies against c-Met
    Patent number: 9068011
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 30, 2015
    Assignee: GENMAB A+S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Combination treatment of CD38-expressing tumors
    Patent number: 9040050
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 26, 2015
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • Human monoclonal antibodies against CD25
    Patent number: 8961968
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: February 24, 2015
    Assignee: Genmab A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER
    Publication number: 20140348833
    Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
    Type: Application
    Filed: March 6, 2014
    Publication date: November 27, 2014
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20140303356
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Applicants: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kamper, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS
    Publication number: 20140271623
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Application
    Filed: July 6, 2012
    Publication date: September 18, 2014
    Applicant: GENMAB A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T.J. Van Den Bremer
  • Monoclonal antibodies against CD32B
    Patent number: 8802089
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: August 12, 2014
    Assignee: Genmab A/S
    Inventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
  • BISPECIFIC ANTIBODIES AGAINST HER2
    Publication number: 20140170148
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Patrick Van Berkel, Kristin Strumane, Aran Frank Labrijn, Joost J. Neijssen, Joyce I. Meesters, Paul Parren, Janine Schuurman
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20140170156
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: November 7, 2013
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
    Publication number: 20140170149
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Joost J. Neijssen, Joyce I. Meesters, Bart De Goeij, Aran Frank Labrijn, Paul Parren, Janine Schuurman
  • HUMAN MONOCLONAL ANTIBODIES TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
    Publication number: 20140141006
    Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: October 16, 2013
    Publication date: May 22, 2014
    Applicant: GENMAB A/S
    Inventors: Jan G. J. VAN DE WINKEL, Marcus Antonius VAN DIJK, Edward HALK, Arnout F. GERRITSEN, Jørgen PETERSEN, Ole BAADSGAARD
  • Human Monoclonal Antibodies Against CD20
    Publication number: 20140093454
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: August 12, 2013
    Publication date: April 3, 2014
    Applicant: GENMAB A/S
    Inventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G.J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
  • HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
    Publication number: 20140030273
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: February 1, 2012
    Publication date: January 30, 2014
    Applicant: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby